Pacific Biosciences (PACB) Q2 2026 earnings summary

Executive summary

• Mark Van Oene was appointed President and CEO, with Christian Henry stepping down but remaining as board member and advisor; leadership change accompanied by a restructuring plan and 8% workforce reduction.

• Q2 2026 revenue was $39.0 million, driven by consumables and new system placements, with strong clinical adoption and the global rollout of SPRQ-Nx chemistry.

• Strategic focus on scaling clinical adoption, global expansion, operational efficiency, and aligning marketing and commercial teams.

• Major scientific publications and population-scale genomics projects validated the clinical utility of HiFi long-read sequencing.

• Restructuring actions were implemented to streamline operations, reduce costs, and support growth initiatives.

Financial highlights

• Q2 2026 revenue was $39.0 million, flat year-over-year; product revenue was $32.95 million, service and other revenue $6.06 million.

• Consumables revenue grew to $20.1 million, instrument revenue was $12.8 million, and service/other revenue was $6.1 million.

• Non-GAAP gross margin was 36%, down from 38% in Q2 2025; non-GAAP net loss was $41.9 million ($0.14 per share), compared to $40.0 million ($0.13 per share) in Q2 2025.

• Ended Q2 with $236.9 million in cash and equivalents, down from $279.5 million at year-end 2025.

• Operating expenses decreased to $56.1 million non-GAAP, down from $58.1 million year-over-year.

Outlook and guidance

• 2026 revenue guidance lowered to $155 million–$165 million, reflecting SPRQ-Nx transition and funding headwinds.

• Non-GAAP gross margin expected at 35%–37% for 2026, with temporary transition costs and elevated compute/memory expenses.

• Non-GAAP operating expenses projected at $215 million–$220 million, lower than $230 million in 2025.

• Year-end cash projected at $175 million–$185 million; cash flow breakeven now expected in 2028, delayed from prior guidance.

• Expense reduction initiatives are anticipated to lower annualized operating expenses by $30–$40 million by end of 2027.